Category: gastroesophageal reflux disease
ROCHESTER, Minn.-- New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, (
Bethesda, MD (Sept. 1, 2009) -- There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.
Bethesda, MD (Aug. 1, 2009) -- Patient satisfaction with their medications and the quality of interactions with their doctor reflect the success of gastroesophageal reflux disease (GERD) therapy, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Bethesda, MD (July 1, 2009) -- Treatment with proton pump inhibitors (PPIs) for eight weeks induces acid-related symptoms like heartburn, acid regurgitation and dyspepsia once treatment is withdrawn in healthy individuals, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
NEW YORK (May 29, 2009) -- Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach.
Bethesda, MD (June 1, 2009) ? Obesity is an independent predictor of inadequate bowel preparation at colonoscopy, and the presence of additional risk factors further increases the likelihood of a poorly cleansed colon, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
OAK BROOK, Ill. - May 14, 2009 - In a review of more than 2,000 patients coded for Barrett's esophagus, electronic diagnosis overestimated the prevalence of the disease according to researchers in California. They found that only 61.9 percent of patients assigned a billing diagnosis code for Barrett's esophagus actually had Barrett's esophagus after a manual record review.
Lansoprazole is a proton pump inhibitor which powerfully suppresses gastric acid production and is widely prescribed for chronic use in gastroesophageal reflux disease. Lansoprazole uncommonly causes chronic watery diarrhea unresponsive to conventional medication as a symptom of collagenous colitis. This association has recently been reported and is not widely known.
In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors( PPIs ). However it has not hitherto been fully determined whether differences in the onset of antisecreatary activity may affect the speed of symptom relief with different PPI.
Bethesda, MD (March 1, 2009) - Although the relationship between alcohol and esophageal squamous cell carcinoma is well established, studies investigating the association between alcohol intake and reflux esophagitis (RE), Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent findings.
According to a new study, more than 60 percent of the children who received surgical fundoplication to control gastroesophageal reflux disease had recurring symptoms of the disease months following surgery. The procedure is the third most common major surgical procedure performed in children. Overall, fundoplication as a treatment for GERD in children needs further evaluation.
